[go: up one dir, main page]

LUC00169I2 - - Google Patents

Download PDF

Info

Publication number
LUC00169I2
LUC00169I2 LU00169C LUC00169C LUC00169I2 LU C00169 I2 LUC00169 I2 LU C00169I2 LU 00169 C LU00169 C LU 00169C LU C00169 C LUC00169 C LU C00169C LU C00169 I2 LUC00169 I2 LU C00169I2
Authority
LU
Luxembourg
Application number
LU00169C
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45565270&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00169(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of LUC00169I2 publication Critical patent/LUC00169I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
LU00169C 2010-08-10 2020-07-06 LUC00169I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37229610P 2010-08-10 2010-08-10
US201161488655P 2011-05-20 2011-05-20

Publications (1)

Publication Number Publication Date
LUC00169I2 true LUC00169I2 (fr) 2024-07-01

Family

ID=45565270

Family Applications (2)

Application Number Title Priority Date Filing Date
LU00168C LUC00168I2 (fr) 2010-08-10 2020-07-06
LU00169C LUC00169I2 (fr) 2010-08-10 2020-07-06

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU00168C LUC00168I2 (fr) 2010-08-10 2020-07-06

Country Status (29)

Country Link
US (11) US8680136B2 (fr)
EP (3) EP3412676B1 (fr)
JP (4) JP6266978B2 (fr)
KR (3) KR102205755B1 (fr)
CN (1) CN103180328B (fr)
AU (1) AU2011289615B2 (fr)
BR (1) BR112013003045B1 (fr)
CA (1) CA2807546C (fr)
CL (1) CL2013000399A1 (fr)
CO (1) CO6680667A2 (fr)
CY (3) CY1123208T1 (fr)
DK (2) DK2603514T3 (fr)
ES (2) ES2691468T3 (fr)
HR (1) HRP20200741T1 (fr)
HU (4) HUE040086T2 (fr)
IL (1) IL224564A (fr)
LT (3) LT3412676T (fr)
LU (2) LUC00168I2 (fr)
MX (1) MX348653B (fr)
MY (2) MY198204A (fr)
NO (2) NO2019014I1 (fr)
NZ (1) NZ607354A (fr)
PL (2) PL3412676T3 (fr)
PT (2) PT2603514T (fr)
RS (1) RS60310B1 (fr)
RU (1) RU2599791C2 (fr)
SG (1) SG187757A1 (fr)
SM (1) SMT202000248T1 (fr)
WO (1) WO2012021455A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102205755B1 (ko) 2010-08-10 2021-01-22 렘펙스 파머수티클스 인코퍼레이티드 고리형 보론산 에스터 유도체의 결정 형태
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US20150119363A1 (en) * 2012-02-15 2015-04-30 Rempex Pharmaceuticals, Inc.. Methods of treating bacterial infections
EP2822931B1 (fr) 2012-03-09 2017-05-03 Inception 2, Inc. Composés de triazolone et leurs utilisations
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) * 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2014052836A2 (fr) 2012-09-27 2014-04-03 Dunman Paul M Procédés et compositions de traitement d'une infection
PT2928898T (pt) 2012-12-07 2021-07-05 Venatorx Pharmaceuticals Inc Inibidores de beta-lactamase
US9676754B2 (en) 2012-12-20 2017-06-13 Inception 2, Inc. Triazolone compounds and uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9642869B2 (en) 2013-01-04 2017-05-09 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN104981239B (zh) * 2013-01-04 2019-01-04 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
JP6346904B2 (ja) 2013-01-10 2018-06-20 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
EP2970340B1 (fr) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamase
CA3011999A1 (fr) * 2013-05-03 2014-11-06 Microbiotix, Inc. Potentialisateurs antimicrobiens
CN105579440A (zh) 2013-09-06 2016-05-11 因森普深2公司 三唑酮化合物及其应用
ES2985626T3 (es) 2014-05-05 2024-11-06 Melinta Therapeutics Inc Sales y polimorfos de derivados cíclicos de éster de ácido borónico y usos terapéuticos de los mismos
RS59488B1 (sr) * 2014-05-05 2019-12-31 Rempex Pharmaceuticals Inc Sinteza boronatnih soli i njihove upotrebe
KR20170007448A (ko) 2014-05-19 2017-01-18 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
EP3882252B1 (fr) 2014-06-11 2025-11-19 Venatorx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamase
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX2016016666A (es) * 2014-07-01 2017-08-08 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
WO2016081297A1 (fr) * 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Dérivés d'esters d'acide boronique cycliques et leurs utilisations thérapeutiques
CN104447610A (zh) * 2014-11-21 2015-03-25 山东金城医药化工股份有限公司 高纯度头孢他啶侧链酸的制备方法
EP3233869B1 (fr) 2014-12-19 2019-09-25 Rempex Pharmaceuticals, Inc. Appareil et procédé à flux continu pour la production de dérivés d'acide boronique
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2982911C (fr) 2015-04-24 2023-10-03 Rempex Pharmaceuticals, Inc. Methodes de traitement d'infections bacteriennes
EP3347008B1 (fr) 2015-09-11 2022-03-09 Venatorx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamases
WO2017100537A1 (fr) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamases
CN109415386B (zh) 2016-06-30 2022-04-19 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
EP3494121B1 (fr) 2016-08-04 2021-10-06 Venatorx Pharmaceuticals, Inc. Composés contenant du bore
SG10201911243WA (en) 2016-12-22 2020-02-27 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
AU2018205327B2 (en) 2017-01-09 2023-11-30 Melinta Therapeutics, Inc. Methods of treating bacterial infections
JOP20190188A1 (ar) 2017-02-01 2019-08-01 Rempex Pharmaceuticals Inc جهاز وعملية تدفق مستمرة لإنتاج مشتق حمض بورونيك
PL3592362T3 (pl) 2017-03-06 2025-06-23 VenatoRx Pharmaceuticals, Inc. Postacie stałe i kompozycje skojarzone zawierające inhibitor beta-laktamaz i ich zastosowania
US11332485B2 (en) 2017-05-26 2022-05-17 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3694864B1 (fr) 2017-10-11 2025-03-05 Qpex Biopharma, Inc. Dérivés d'acide boronique et synthèse de ces derniers
CA3080763A1 (fr) * 2017-11-01 2019-05-09 Melinta Therapeutics, Inc. Synthese de derives d'esters de boronate et utilisations associees
WO2019204419A1 (fr) 2018-04-20 2019-10-24 The Medicines Company (San Diego), Llc Dérivés d'acide boronique et leurs utilisations thérapeutiques
WO2019226931A1 (fr) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Inhibiteurs de protéine de liaison à la pénicilline
CN111039965B (zh) * 2018-10-12 2020-12-01 新发药业有限公司 一种法硼巴坦的简便制备方法
US20240173374A1 (en) * 2021-02-25 2024-05-30 Ohio State Innovation Foundation Liposomal formulations of boronic acid containing active agents
CN113214302B (zh) * 2021-04-23 2022-06-24 四川大学 一种抑制金属β-内酰胺酶和/或丝氨酸β-内酰胺酶的3-取代五元环状硼酸酯衍生物
US20240390335A1 (en) * 2021-11-09 2024-11-28 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Pharmaceutical composition containing beta-lactam compound and use thereof
GB202306835D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3686398A (en) 1970-07-20 1972-08-22 Chevron Res 10,9-boroxarophenanthrene as fungicides
US4194047A (en) 1975-11-21 1980-03-18 Merck & Co., Inc. Substituted N-methylene derivatives of thienamycin
US4260543A (en) 1978-07-03 1981-04-07 Merck & Co., Inc. Crystalline N-formimidoyl thienamycin
US4409214A (en) 1979-11-19 1983-10-11 Fujisawa Pharmaceutical, Co., Ltd. 7-Acylamino-3-vinylcephalosporanic acid derivatives and processes for the preparation thereof
US4353807A (en) 1981-03-24 1982-10-12 Mobil Oil Corporation Lubricants and fuels containing boroxarophenanthrene compounds
FR2573070B1 (fr) 1984-11-13 1987-01-30 Rhone Poulenc Sante Procede de preparation de composes carbonyles
FR2574070B1 (fr) 1984-11-30 1987-02-27 Stam Catalyseur de prise de mortiers d'anhydrite projetes a la lance, a resistance amelioree a un stockage a temperature et humidite elevees, et utilisation d'un tel catalyseur
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
CA1283404C (fr) 1986-07-01 1991-04-23 Shigeru Sanai Composes de cephalosporine, procede de preparation et agents antibacteriens
ZA893284B (en) 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
US5442100A (en) 1992-08-14 1995-08-15 The Procter & Gamble Company β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids
US5888998A (en) 1997-04-24 1999-03-30 Synphar Laboratories, Inc. 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors
US6075014A (en) 1997-06-13 2000-06-13 Northwestern University Inhibitors of β-lactamases and uses therefor
US6184363B1 (en) 1997-06-13 2001-02-06 Northwestern University Inhibitors of β-lactamases and uses therefor
AU2190400A (en) 1998-12-16 2000-07-03 Northwestern University Inhibitors of beta-lactamases and uses therefor
AU3124300A (en) 1998-12-16 2000-07-03 Northwestern University Inhibitors of beta-lactamases and uses therefor
PT1216239E (pt) 1999-09-25 2004-05-31 Smithkline Beecham Plc Derivados de piperazina como antagonistas de 5-ht1b
AU762935B2 (en) 1999-10-28 2003-07-10 Merck & Co., Inc. Novel succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections
WO2002022137A1 (fr) 2000-09-12 2002-03-21 Shoichet Brian K Analogues de $g(b)-lactamine et utilisations de ceux-ci
BR0113861A (pt) 2000-09-14 2004-01-27 Pantherix Ltd Derivados de ácidos 3-(heteroaril acetamido)-2-oxo-azetidina-1-sulfÈnicos como agentes antibacterianos
US6586615B1 (en) 2001-01-10 2003-07-01 Bristol-Myers Squibb Company α-aminoboronic acids prepared by novel synthetic methods
DE10118698A1 (de) 2001-04-17 2002-11-07 Jerini Ag Verfahren zur Immobilisierung und damit hergestellte Anordnungen von Verbindungen auf einer planaren Oberfläche
AU2002360732A1 (en) 2001-12-26 2003-07-24 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
JP2003229277A (ja) 2002-02-04 2003-08-15 Matsushita Electric Ind Co Ltd 発光素子材料およびそれを用いた発光素子並びに装置
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
AU2003261974A1 (en) 2002-09-11 2004-04-30 Kureha Chemical Industry Company, Limited Amine compounds and use thereof
EP2325225B2 (fr) 2002-10-30 2019-12-11 Sumitomo Chemical Company, Limited Composés de copolymère d'aryle et dispositif électroluminescents à polymère fabriqués à partir de ceux-ci
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
MXPA05006798A (es) 2002-12-20 2006-03-09 Migenix Corp Ligandos de adenina nucleotido translocasa (ant) y composiciones y metodos relacionados a estos.
TW200418791A (en) 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
JP4233365B2 (ja) 2003-03-25 2009-03-04 三井化学株式会社 アザジオール錯体化合物、及び該化合物を用いる光記録媒体
US7842941B2 (en) 2003-10-06 2010-11-30 Sumitomo Chemical Company, Limited Aromatic compound
DE602004008098T8 (de) 2003-10-10 2008-04-17 Pfizer Products Inc., Groton Substituierte 2h-[1,2,4]triazolo[4,3-a]pyrazine als gsk-3-inhibitoren
WO2005047297A1 (fr) 2003-11-12 2005-05-26 Phenomix Corporation Composés heterocycliques d'acide boronique
TW200600494A (en) 2004-03-08 2006-01-01 Chugai Pharmaceutical Co Ltd Bisphenyl compounds useful as vitamin d3 receptor agonists
US20060019116A1 (en) 2004-07-22 2006-01-26 Eastman Kodak Company White electroluminescent device with anthracene derivative host
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US20060178357A1 (en) 2005-02-10 2006-08-10 Buynak John D Chphalosporin-derived mercaptans as inhibitors of serine and metallo-beta-lactamases
KR101456815B1 (ko) 2005-02-16 2014-10-31 아나코르 파마슈티칼스 인코포레이티드 보론함유 소분자
KR100945763B1 (ko) 2005-02-22 2010-03-08 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 제조 방법
US9184428B2 (en) 2005-03-15 2015-11-10 Uchicago Argonne Llc Non-aqueous electrolytes for lithium ion batteries
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
TW200734311A (en) 2005-11-21 2007-09-16 Astrazeneca Ab New compounds
DK2484680T3 (da) 2005-12-07 2013-09-08 Basilea Pharmaceutica Ag Nyttige kombinationer af monolactam-antibiotika med beta-lactamase-inhibitorer
PL1988779T3 (pl) 2006-02-16 2015-10-30 Anacor Pharmaceuticals Inc Małe cząsteczki zawierające bor jako środki przeciwzapalne
EP2069347A2 (fr) 2006-09-27 2009-06-17 Merck & Co., Inc. Nouveaux inhibiteurs de bêta-lactamase
KR101320718B1 (ko) 2007-03-23 2013-10-21 바실리어 파마슈티카 아게 세균 감염 치료용 조합 약제
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
KR20100113485A (ko) 2007-11-13 2010-10-21 프로테즈 파마슈티칼스, 인크. 베타-락타마제 억제제
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
WO2009091856A2 (fr) 2008-01-18 2009-07-23 Merck & Co., Inc. Inhibiteurs de bêta-lactamase
US8129398B2 (en) 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2009140309A2 (fr) 2008-05-12 2009-11-19 Anacor Pharmaceuticals, Inc. Petites molécules contenant du bore
WO2009139834A1 (fr) 2008-05-13 2009-11-19 Poniard Pharmaceuticals, Inc. Composés bioactifs pour le traitement du cancer et des maladies neurodégénératives
CA2744231A1 (fr) * 2008-12-17 2010-07-15 Anacor Pharmaceuticals, Inc. Formes polymorphiques du (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2]oxaborol-1-ol
US20120046242A1 (en) 2008-12-24 2012-02-23 Massachusetts Institute Of Technology Molecular activators of the wnt/beta-catenin pathway
WO2010097675A1 (fr) 2009-02-27 2010-09-02 Dhanuka Laboratories Ltd. Procédé de préparation amélioré pour le cefpodoxime proxétil
AR076667A1 (es) 2009-05-12 2011-06-29 Novartis Int Pharm Ltd Inhibidores de beta-lactamasa
AU2010259002B2 (en) 2009-06-08 2014-03-20 Nantbio, Inc. Triazine derivatives and their therapeutical applications
AU2010281439A1 (en) 2009-07-28 2012-03-15 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
EP2539348A4 (fr) 2010-02-26 2013-07-24 Gary Igor Dmitrienko Dérivés de la céphalosporine utiles comme inhibiteurs de la -lactamase et leurs compositions et procédés d'utilisation
MX2012011298A (es) 2010-03-31 2012-11-06 Millennium Pharm Inc Derivados del acido 1-amino-2-ciclopropiletilboronico.
US20110288063A1 (en) 2010-05-19 2011-11-24 Naeja Pharmaceutical Inc. Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors
JP5603487B2 (ja) 2010-06-10 2014-10-08 テクニオン リサーチ アンド ディベラップメント ファウンデイション リミテッド ヨウ化物の調製のためのプロセス
KR102205755B1 (ko) 2010-08-10 2021-01-22 렘펙스 파머수티클스 인코퍼레이티드 고리형 보론산 에스터 유도체의 결정 형태
PL2632927T3 (pl) 2010-10-26 2016-09-30 Boroniany jako inhibitory arginazy
WO2012067664A1 (fr) 2010-11-18 2012-05-24 Glaxo Group Limited Composés
EP2487159A1 (fr) 2011-02-11 2012-08-15 MSD Oss B.V. Inhibiteurs du RORgammaT
EP2508506A1 (fr) 2011-04-08 2012-10-10 LEK Pharmaceuticals d.d. Préparation d'intermédiaires de la sitagliptine
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013053372A1 (fr) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Inhibiteurs de type acide boronique de bêta-lactamases
WO2013056163A1 (fr) 2011-10-14 2013-04-18 The Regents Of The University Of California Inhibiteurs de bêta-lactamase
EA201400735A1 (ru) 2011-12-22 2015-04-30 Арес Трейдинг С.А. Производные альфа-амино бороновой кислоты, селективные ингибиторы иммунопротеасомы
EP2802593A1 (fr) 2012-01-09 2014-11-19 The University of Tromsoe Composés thérapeutiques contenant du bore
EP2615080A1 (fr) 2012-01-12 2013-07-17 LEK Pharmaceuticals d.d. Préparation d'ingrédients pharmaceutiques actifs de type acide aminés ß purs optiquement et intermédiaires associés
US20150119363A1 (en) 2012-02-15 2015-04-30 Rempex Pharmaceuticals, Inc.. Methods of treating bacterial infections
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
PT2928898T (pt) 2012-12-07 2021-07-05 Venatorx Pharmaceuticals Inc Inibidores de beta-lactamase
CN104981239B (zh) 2013-01-04 2019-01-04 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9642869B2 (en) 2013-01-04 2017-05-09 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US8999885B2 (en) 2013-01-09 2015-04-07 General Electric Company Methods of activating charcoal resulting from biomass gasification
JP6346904B2 (ja) 2013-01-10 2018-06-20 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
EP2970340B1 (fr) 2013-03-14 2020-02-12 Venatorx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamase
AU2014227571B2 (en) 2013-03-15 2017-02-02 Intrexon Corporation Boron-containing diacylhydrazines
RS59488B1 (sr) 2014-05-05 2019-12-31 Rempex Pharmaceuticals Inc Sinteza boronatnih soli i njihove upotrebe
ES2985626T3 (es) 2014-05-05 2024-11-06 Melinta Therapeutics Inc Sales y polimorfos de derivados cíclicos de éster de ácido borónico y usos terapéuticos de los mismos
KR20170007448A (ko) 2014-05-19 2017-01-18 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
US9511142B2 (en) * 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3882252B1 (fr) 2014-06-11 2025-11-19 Venatorx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamase
MX2016016666A (es) 2014-07-01 2017-08-08 Rempex Pharmaceuticals Inc Derivados de acido boronico y usos terapeuticos de los mismos.
WO2016065282A1 (fr) 2014-10-24 2016-04-28 The Regents Of The University Of Michigan Formulation nasale, kit nasal, et procédé d'augmentation des taux nasaux d'oxyde nitrique (no)
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2982911C (fr) 2015-04-24 2023-10-03 Rempex Pharmaceuticals, Inc. Methodes de traitement d'infections bacteriennes
CN109415386B (zh) 2016-06-30 2022-04-19 Qpex生物制药有限公司 硼酸衍生物及其治疗用途

Also Published As

Publication number Publication date
US20180207183A1 (en) 2018-07-26
EP3666778B1 (fr) 2021-11-10
JP2021073212A (ja) 2021-05-13
US20190076449A1 (en) 2019-03-14
PT2603514T (pt) 2018-11-09
AU2011289615B2 (en) 2015-05-07
US11684629B2 (en) 2023-06-27
ES2691468T3 (es) 2018-11-27
US20160220591A1 (en) 2016-08-04
MX348653B (es) 2017-06-21
EP2603514A4 (fr) 2014-10-29
US20250064838A1 (en) 2025-02-27
US20200222434A1 (en) 2020-07-16
RU2599791C2 (ru) 2016-10-20
US10183034B2 (en) 2019-01-22
DK3412676T3 (da) 2020-05-04
US20120040932A1 (en) 2012-02-16
ES2789177T3 (es) 2020-10-26
BR112013003045B1 (pt) 2021-08-31
EP3412676A1 (fr) 2018-12-12
US9694025B2 (en) 2017-07-04
MY188960A (en) 2022-01-14
CY2020019I2 (el) 2020-11-25
NZ607354A (en) 2015-01-30
US9296763B2 (en) 2016-03-29
CY2020020I1 (el) 2020-11-25
LTC3412676DI2 (lt) 2022-05-10
PL2603514T3 (pl) 2019-04-30
NO2019013I1 (no) 2019-03-28
DK2603514T3 (en) 2018-10-29
EP3412676B1 (fr) 2020-02-12
US20230277571A1 (en) 2023-09-07
JP6854861B2 (ja) 2021-04-07
NO2019014I1 (no) 2019-03-28
RU2013104951A (ru) 2014-09-20
JP6266978B2 (ja) 2018-01-24
CA2807546C (fr) 2022-08-23
US10639318B2 (en) 2020-05-05
CY2020019I1 (el) 2020-11-25
US11090319B2 (en) 2021-08-17
KR20130099923A (ko) 2013-09-06
PT3412676T (pt) 2020-05-19
CO6680667A2 (es) 2013-05-31
JP2017052794A (ja) 2017-03-16
EP3666778A1 (fr) 2020-06-17
US8680136B2 (en) 2014-03-25
HUE048859T2 (hu) 2020-08-28
HUS1900017I1 (hu) 2019-05-28
EP2603514A1 (fr) 2013-06-19
MY198204A (en) 2023-08-11
JP7227282B2 (ja) 2023-02-21
IL224564A (en) 2017-02-28
US20180071325A1 (en) 2018-03-15
LT3412676T (lt) 2020-07-27
CN103180328A (zh) 2013-06-26
KR102087313B1 (ko) 2020-03-11
CY2020020I2 (el) 2020-11-25
AU2011289615A1 (en) 2013-03-21
RS60310B1 (sr) 2020-07-31
LUC00168I2 (fr) 2024-07-01
HUS1900018I1 (hu) 2019-05-28
PL3412676T3 (pl) 2021-04-06
KR20190066084A (ko) 2019-06-12
KR20200028043A (ko) 2020-03-13
LTC3412676I2 (lt) 2022-09-12
US10172874B2 (en) 2019-01-08
HRP20200741T1 (hr) 2020-10-16
EP2603514B1 (fr) 2018-07-18
KR102205755B1 (ko) 2021-01-22
MX2013001517A (es) 2013-04-29
HUE040086T2 (hu) 2019-02-28
JP6602742B2 (ja) 2019-11-06
US12171772B2 (en) 2024-12-24
LTPA2020521I1 (lt) 2020-08-10
SG187757A1 (en) 2013-03-28
US20220125813A1 (en) 2022-04-28
US20130345172A1 (en) 2013-12-26
JP2013535502A (ja) 2013-09-12
CY1123208T1 (el) 2020-11-25
KR101987091B1 (ko) 2019-06-10
US10004758B2 (en) 2018-06-26
LTPA2020519I1 (lt) 2020-08-10
CN103180328B (zh) 2016-10-26
WO2012021455A1 (fr) 2012-02-16
US20180214465A1 (en) 2018-08-02
JP2020002178A (ja) 2020-01-09
BR112013003045A2 (pt) 2016-06-14
CL2013000399A1 (es) 2013-08-23
SMT202000248T1 (it) 2020-07-08
CA2807546A1 (fr) 2012-02-16

Similar Documents

Publication Publication Date Title
BR112013008959A2 (fr)
BR112012030039A2 (fr)
BR112012019354A2 (fr)
BR112012028408A2 (fr)
BR112012031500A2 (fr)
BR112012017960A2 (fr)
BR112012002126A2 (fr)
BR112013006400A2 (fr)
BR112012031826A2 (fr)
BR112012023249A2 (fr)
BR112012028186A2 (fr)
BR112012016456A2 (fr)
BR112012018256A2 (fr)
BR112013010949A2 (fr)
BR112012023265A2 (fr)
BR112013003284A2 (fr)
BR112012022788A2 (fr)
BR112012016895A2 (fr)
BR112013006825A2 (fr)
BR112012023446A2 (fr)
BR112012028859A2 (fr)
BR112013007728A2 (fr)
BR112012030078A2 (fr)
BR122017023128A2 (fr)
BR112013007731A2 (fr)